ArticleCell biochemistry and biophysics2026
Ergothioneine Modulates Inflammatory Signaling in LPS-Stimulated RAW 264.7 Macrophages.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ergothioneine (EGT), a naturally occurring antioxidant abundant in Hericium erinaceus, has been implicated in inflammation-related disorders, including inflammatory bowel disease (IBD). A validated HPLC-DAD method was developed for EGT quantification in H. erinaceus, demonstrating satisfactory specificity, linearity, precision, and accuracy. Network pharmacology analysis identified shared targets between EGT-associated proteins and IBD-related genes, with HSP90AA1 emerging as a key candidate. Molecular docking revealed stable binding of EGT within the HSP90AA1 active site. In lipopolysaccharide-stimulated RAW 264.7 macrophages, EGT significantly reduced the expression of pro-inflammatory mediators, including inducible nitric oxide synthase and cyclooxygenase-2, while modulating PPARγ expression. These findings provide integrated chemical and mechanistic evidence supporting EGT as a bioactive constituent of H. erinaceus with potential relevance for modulating intestinal inflammation. However, further studies are required to validate its therapeutic relevance in disease-specific models.
Indexed as
Identifiers
42789008What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.